Alignment Healthcare, Inc. $ALHC Shares Acquired by Vanguard Group Inc.

Vanguard Group Inc. lifted its holdings in Alignment Healthcare, Inc. (NASDAQ:ALHC) by 5.0% in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 13,968,584 shares of the company’s stock after purchasing an additional 664,769 shares during the quarter. Vanguard Group Inc. owned 6.98% of Alignment Healthcare worth $243,752,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. PNC Financial Services Group Inc. boosted its holdings in shares of Alignment Healthcare by 205.6% in the third quarter. PNC Financial Services Group Inc. now owns 3,459 shares of the company’s stock valued at $60,000 after acquiring an additional 2,327 shares in the last quarter. Rhumbline Advisers boosted its stake in Alignment Healthcare by 8.3% during the third quarter. Rhumbline Advisers now owns 200,065 shares of the company’s stock valued at $3,491,000 after buying an additional 15,382 shares in the last quarter. Navellier & Associates Inc. acquired a new position in Alignment Healthcare during the third quarter worth about $525,000. Principal Financial Group Inc. raised its position in Alignment Healthcare by 40.1% in the third quarter. Principal Financial Group Inc. now owns 167,376 shares of the company’s stock worth $2,921,000 after acquiring an additional 47,895 shares in the last quarter. Finally, Arizona State Retirement System lifted its holdings in Alignment Healthcare by 33.1% in the 3rd quarter. Arizona State Retirement System now owns 40,967 shares of the company’s stock valued at $715,000 after acquiring an additional 10,195 shares during the last quarter. Institutional investors own 86.19% of the company’s stock.

Alignment Healthcare Stock Performance

Shares of Alignment Healthcare stock opened at $19.22 on Friday. Alignment Healthcare, Inc. has a 12 month low of $11.63 and a 12 month high of $23.87. The company has a quick ratio of 1.61, a current ratio of 1.61 and a debt-to-equity ratio of 1.99. The stock has a market cap of $3.85 billion, a PE ratio of -1,920.08, a price-to-earnings-growth ratio of 4.90 and a beta of 1.16. The business has a fifty day simple moving average of $20.99 and a 200-day simple moving average of $18.54.

Alignment Healthcare (NASDAQ:ALHC) last announced its quarterly earnings data on Thursday, February 26th. The company reported ($0.05) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.15) by $0.10. Alignment Healthcare had a negative return on equity of 0.53% and a negative net margin of 0.02%.The firm had revenue of $1.01 billion during the quarter, compared to the consensus estimate of $1 billion. During the same period in the prior year, the business earned ($0.16) EPS. The business’s revenue for the quarter was up 44.4% on a year-over-year basis. On average, sell-side analysts anticipate that Alignment Healthcare, Inc. will post -0.69 EPS for the current fiscal year.

Insider Buying and Selling at Alignment Healthcare

In other Alignment Healthcare news, insider Andreas P. Wagner sold 22,238 shares of Alignment Healthcare stock in a transaction on Tuesday, February 10th. The shares were sold at an average price of $20.47, for a total transaction of $455,211.86. Following the completion of the sale, the insider owned 169,805 shares of the company’s stock, valued at $3,475,908.35. This trade represents a 11.58% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider Hyong Kim sold 16,506 shares of the business’s stock in a transaction on Tuesday, January 6th. The shares were sold at an average price of $21.35, for a total transaction of $352,403.10. Following the transaction, the insider owned 333,133 shares in the company, valued at approximately $7,112,389.55. This represents a 4.72% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 2,125,938 shares of company stock valued at $41,799,570 in the last 90 days. Corporate insiders own 7.00% of the company’s stock.

Key Headlines Impacting Alignment Healthcare

Here are the key news stories impacting Alignment Healthcare this week:

• Positive Sentiment: Q4 results beat near‑term expectations — Alignment reported ($0.05) EPS vs. consensus (~$0.15 loss) and revenue of ~$1.01B, up ~44% year‑over‑year, showing strong top‑line growth. Alignment Healthcare Reports Fourth Quarter and Full‑Year 2025 Results
• Positive Sentiment: Company highlighted record revenue and membership gains, supporting continued Medicare Advantage enrollment momentum that underpins revenue visibility. Alignment Healthcare Inc (ALHC) Q4 2025 Earnings Call Highlights
• Neutral Sentiment: Analyst writeups and metric comparisons confirmed the beat but note persistent negative margins and ROE; these pieces provide context on profitability trends and model updates. Zacks — Key Metrics Versus Estimates
• Neutral Sentiment: Conference call / press release and filings are available for details on membership trends, medical cost assumptions and guidance drivers for 2026. Quarterly Report / Press Release PDF
• Neutral Sentiment: Reported short‑interest data in public feeds appears erroneous (zeros/NaN); no reliable short‑interest signal from those entries. Market data / profile
• Negative Sentiment: Forward guidance disappointed: Q1 revenue guidance (~$1.2B) below the ~ $1.3B street estimate and FY 2026 revenue guidance of $5.1B–$5.2B sits at or slightly under consensus — investors reacted to the softer top‑line outlook. Guidance details in Earnings Release
• Negative Sentiment: Profitability remains a concern — the company still shows a small negative net margin and negative return on equity, and management did not provide explicit EPS guidance for 2026, leaving investors uncertain on near‑term earnings conversion. Zacks — Q4 Loss, Beats Revenue Estimates

Analyst Ratings Changes

ALHC has been the subject of several recent research reports. Piper Sandler increased their target price on shares of Alignment Healthcare from $20.00 to $30.00 and gave the company an “overweight” rating in a research note on Tuesday, January 6th. Robert W. Baird set a $28.00 price objective on Alignment Healthcare in a research report on Friday, January 30th. The Goldman Sachs Group restated a “buy” rating and issued a $22.00 target price on shares of Alignment Healthcare in a report on Monday, November 3rd. Wall Street Zen raised Alignment Healthcare from a “hold” rating to a “buy” rating in a report on Saturday, February 7th. Finally, UBS Group lifted their price target on Alignment Healthcare from $18.00 to $21.00 and gave the stock a “neutral” rating in a research note on Wednesday, January 14th. One research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $23.95.

Alignment Healthcare Profile

Alignment Healthcare, Inc (NASDAQ: ALHC) is a health care company specializing in value-based care for Medicare Advantage beneficiaries. The company leverages an integrated care model that combines in-home clinical services, telehealth capabilities and digital health tools to manage chronic conditions, improve outcomes and enhance patient experience.

At the core of Alignment Healthcare’s approach is a proprietary technology platform that aggregates real-time clinical and claims data to support preventive care, risk stratification and personalized care plans.